Brainstorm Cell Therapeutics | BCLI - Operating Profit

Stock Price
0.85
Daily Change
-0.02 -1.73%
Monthly
-5.56%
Yearly
6.92%
Q2 Forecast
0.90

Brainstorm Cell Therapeutics reported $-2.24M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Alterity Therapeutics Limited AUD -8.07M 302.4K Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
Brainstorm Cell Therapeutics USD -2.24M 197K Dec/2025
Cipla INR 9.77B 6.21B Dec/2025
Clal Biotechnology ILS -1.74M 7.46M Dec/2022
Compugen USD 56.04M 63.93M Dec/2025
CSL USD 2.64B 1.97B Dec/2025
Cytokinetics USD -178.37M 11.61M Dec/2025
Gilead Sciences USD 2.96B 551M Dec/2025
Grifols EUR 320.55M 91.01M Dec/2025
Halozyme Therapeutics USD -88.41M 306.33M Dec/2025
Mesoblast USD -30.96M 11.14M Dec/2025